Age groups | 30–39 years | 5 [14.2%] |
40–49 years | 11 [31.4%] | |
50–59 years | 16 [45.7%] | |
> 59 years | 3 [8.5%] | |
Sex | Male | 32 [91.4%] |
Female | 3 [8.5%] | |
Pathology | Transitional cell ca. | 31 [88.5%] |
Squamous cell ca. | 4 [11.4%] | |
Groups | Group A: initial staging | 18 [51.4%] |
 | Group B: post-therapeutic evaluation | 17 (48.6%) |